X4 Pharmaceuticals Stock Working Capital

XFOR Stock

USD 0.34 0.03 8.11%

X4 Pharmaceuticals fundamentals help investors to digest information that contributes to X4 Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of XFOR Stock. The fundamental analysis module provides a way to measure X4 Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to X4 Pharmaceuticals stock.

	Last Reported	Projected for Next Year
Net Working Capital	99.2 M	89.4 M
Change In Working Capital	344 K	361.2 K

As of 11/25/2024, Change In Working Capital is likely to grow to about 361.2 K, while Net Working Capital is likely to drop slightly above 89.4 M.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

X4 Pharmaceuticals Company Working Capital Analysis

X4 Pharmaceuticals' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Working Capital

Current Assets

-

Current Liabilities

More About Working Capital | All Equity Analysis

Current X4 Pharmaceuticals Working Capital

99.21 M

Most of X4 Pharmaceuticals' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, X4 Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

XFOR Working Capital Driver Correlations

Understanding the fundamental principles of building solid financial models for X4 Pharmaceuticals is extremely important. It helps to project a fair market value of XFOR Stock properly, considering its historical fundamentals such as Working Capital. Since X4 Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of X4 Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of X4 Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Net Tangible Assets	Long Term Debt	Short Long Term Debt	Property Plant Equipment	Long Term Debt Total	Capital Surpluse	Net Invested Capital	Net Working Capital	Capital Stock	Good Will	Deferred Long Term Liab
Total Assets		0.94	0.35	-0.91	-0.78	0.75	-0.41	0.39	0.99	-0.29	0.63	0.84	0.81	-0.92	0.52	0.91	0.82	0.8	0.71	0.56	-0.65	-0.32
Total Stockholder Equity	0.94		0.46	-0.96	-0.62	0.56	-0.18	0.07	0.94	-0.47	0.44	0.72	0.61	-0.94	0.53	0.77	0.63	0.72	0.58	0.36	-0.45	-0.21
Current Deferred Revenue	0.35	0.46		-0.5	-0.23	0.25	-0.07	-0.22	0.43	-0.16	0.22	0.0	0.08	-0.41	0.02	0.04	0.06	0.06	0.06	0.17	-0.13	-0.21
Net Debt	-0.91	-0.96	-0.5		0.55	-0.53	0.1	-0.07	-0.93	0.37	-0.44	-0.68	-0.5	0.84	-0.32	-0.69	-0.57	-0.72	-0.67	-0.36	0.41	0.15
Retained Earnings	-0.78	-0.62	-0.23	0.55		-0.98	0.64	-0.65	-0.78	0.06	-0.94	-0.7	-0.88	0.74	-0.32	-0.74	-0.87	-0.52	-0.51	-0.91	0.93	0.72
Accounts Payable	0.75	0.56	0.25	-0.53	-0.98		-0.71	0.71	0.75	0.04	0.97	0.72	0.85	-0.65	0.24	0.71	0.83	0.56	0.59	0.95	-0.92	-0.75
Net Receivables	-0.41	-0.18	-0.07	0.1	0.64	-0.71		-0.76	-0.37	-0.23	-0.61	-0.61	-0.71	0.23	-0.43	-0.58	-0.62	-0.51	-0.48	-0.62	0.7	0.56
Total Liab	0.39	0.07	-0.22	-0.07	-0.65	0.71	-0.76		0.37	0.45	0.67	0.54	0.75	-0.16	0.1	0.61	0.73	0.41	0.55	0.7	-0.72	-0.38
Total Current Assets	0.99	0.94	0.43	-0.93	-0.78	0.75	-0.37	0.37		-0.28	0.65	0.8	0.78	-0.91	0.43	0.87	0.81	0.77	0.71	0.58	-0.65	-0.33
Short Term Debt	-0.29	-0.47	-0.16	0.37	0.06	0.04	-0.23	0.45	-0.28		-0.03	-0.22	-0.1	0.38	-0.17	-0.18	0.02	-0.25	-0.08	0.02	-0.13	0.16
Common Stock	0.63	0.44	0.22	-0.44	-0.94	0.97	-0.61	0.67	0.65	-0.03		0.61	0.76	-0.53	0.02	0.56	0.73	0.44	0.53	0.99	-0.88	-0.83
Net Tangible Assets	0.84	0.72	0.0	-0.68	-0.7	0.72	-0.61	0.54	0.8	-0.22	0.61		0.77	-0.65	0.48	0.89	0.75	0.96	0.88	0.58	-0.63	-0.45
Long Term Debt	0.81	0.61	0.08	-0.5	-0.88	0.85	-0.71	0.75	0.78	-0.1	0.76	0.77		-0.71	0.52	0.91	0.94	0.63	0.57	0.73	-0.82	-0.48
Short Long Term Debt	-0.92	-0.94	-0.41	0.84	0.74	-0.65	0.23	-0.16	-0.91	0.38	-0.53	-0.65	-0.71		-0.61	-0.78	-0.72	-0.57	-0.4	-0.45	0.57	0.29
Property Plant Equipment	0.52	0.53	0.02	-0.32	-0.32	0.24	-0.43	0.1	0.43	-0.17	0.02	0.48	0.52	-0.61		0.63	0.5	0.42	0.1	-0.04	-0.3	0.06
Long Term Debt Total	0.91	0.77	0.04	-0.69	-0.74	0.71	-0.58	0.61	0.87	-0.18	0.56	0.89	0.91	-0.78	0.63		0.9	0.83	0.73	0.52	-0.67	-0.24
Capital Surpluse	0.82	0.63	0.06	-0.57	-0.87	0.83	-0.62	0.73	0.81	0.02	0.73	0.75	0.94	-0.72	0.5	0.9		0.61	0.59	0.7	-0.9	-0.36
Net Invested Capital	0.8	0.72	0.06	-0.72	-0.52	0.56	-0.51	0.41	0.77	-0.25	0.44	0.96	0.63	-0.57	0.42	0.83	0.61		0.92	0.41	-0.44	-0.28
Net Working Capital	0.71	0.58	0.06	-0.67	-0.51	0.59	-0.48	0.55	0.71	-0.08	0.53	0.88	0.57	-0.4	0.1	0.73	0.59	0.92		0.52	-0.49	-0.3
Capital Stock	0.56	0.36	0.17	-0.36	-0.91	0.95	-0.62	0.7	0.58	0.02	0.99	0.58	0.73	-0.45	-0.04	0.52	0.7	0.41	0.52		-0.87	-0.84
Good Will	-0.65	-0.45	-0.13	0.41	0.93	-0.92	0.7	-0.72	-0.65	-0.13	-0.88	-0.63	-0.82	0.57	-0.3	-0.67	-0.9	-0.44	-0.49	-0.87		0.63
Deferred Long Term Liab	-0.32	-0.21	-0.21	0.15	0.72	-0.75	0.56	-0.38	-0.33	0.16	-0.83	-0.45	-0.48	0.29	0.06	-0.24	-0.36	-0.28	-0.3	-0.84	0.63

Click cells to compare fundamentals

Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.

Competition

Predict X4 Pharmaceuticals

Working Capital Over Time

XFOR Capital Surpluse

Capital Surpluse

283.07 Million

At this time, X4 Pharmaceuticals' Capital Surpluse is relatively stable compared to the past year.

As per the company's disclosures, X4 Pharmaceuticals has a Working Capital of 99.21 M. This is 76.69% lower than that of the Biotechnology sector and 81.58% lower than that of the Health Care industry. The working capital for all United States stocks is 93.29% higher than that of the company.

XFOR Working Capital Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses X4 Pharmaceuticals' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of X4 Pharmaceuticals could also be used in its relative valuation, which is a method of valuing X4 Pharmaceuticals by comparing valuation metrics of similar companies.

X4 Pharmaceuticals is currently under evaluation in working capital category among its peers.

XFOR Fundamentals

	Return On Equity	0.22
	Return On Asset	-0.4
	Profit Margin	31.32 %
	Operating Margin	(60.21) %
	Current Valuation	870.71 K
	Shares Outstanding	170.55 M
	Shares Owned By Insiders	1.14 %
	Shares Owned By Institutions	67.66 %
	Number Of Shares Shorted	11.42 M
	Price To Book	0.97 X
	Price To Sales	102.39 X
	Gross Profit	3 M
	EBITDA	(107.1 M)
	Net Income	(101.17 M)
	Cash And Equivalents	47.38 M
	Cash Per Share	0.69 X
	Total Debt	58.28 M
	Debt To Equity	1.28 %
	Current Ratio	2.39 X
	Book Value Per Share	0.30 X
	Cash Flow From Operations	(96.51 M)
	Short Ratio	8.64 X
	Earnings Per Share	(0.08) X
	Target Price	2.68
	Number Of Employees	127
	Beta	0.39
	Market Capitalization	57.64 M
	Total Asset	147.26 M
	Retained Earnings	(477.9 M)
	Working Capital	99.21 M
	Net Asset	147.26 M

About X4 Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze X4 Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of X4 Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of X4 Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Pair Trading with X4 Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if X4 Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in X4 Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with XFOR Stock

0.82	ME	23Andme Holding	Pair Corr
0.76	VALN	Valneva SE ADR	Pair Corr
0.66	JNJ	Johnson Johnson Sell-off Trend	Pair Corr

Moving against XFOR Stock

0.64	KZR	Kezar Life Sciences	Pair Corr
0.37	MLYS	Mineralys Therapeutics,	Pair Corr
0.31	MDGL	Madrigal Pharmaceuticals	Pair Corr

The ability to find closely correlated positions to X4 Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace X4 Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back X4 Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling X4 Pharmaceuticals to buy it.

The correlation of X4 Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as X4 Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if X4 Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for X4 Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for XFOR Stock Analysis

When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC